SCOPUS 정보 검색 플랫폼

Gut

Volumn 60, Issue 6, 2011, Pages 741-742

Does it all ADA up? Adalimumab for ulcerative colitis

(1) Travis, Simon a

a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; INFLIXIMAB; PLACEBO;

CLINICAL ASSESSMENT; DOSE RESPONSE; DRUG EFFICACY; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; SCORING SYSTEM; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; GASTROINTESTINAL AGENTS; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79955870420 PISSN: 00175749 EISSN: 14683288 Source Type: Journal
DOI: 10.1136/gut.2010.233403 Document Type: Note

Times cited : (8)

References (8)

1
- 79955859430
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial
- Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7.
- (2011) Gut , vol.60 , pp. 780-787
- Reinisch, W.¹ Sandborn, W.J.² Hommes, D.W.³

2
- 28844473957
- Infliximab for induction and maintenance therapy for ulcerative colitis
- DOI 10.1056/NEJMoa050516
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
- (2005) New England Journal of Medicine , vol.353 , Issue.23 , pp. 2462-2476
- Rutgeerts, P.¹ Sandborn, W.J.² Feagan, B.G.³ Reinisch, W.⁴ Olson, A.⁵ Johanns, J.⁶ Travers, S.⁷ Rachmilewitz, D.⁸ Hanauer, S.B.⁹ Lichtenstein, G.R.¹⁰ De Villiers, W.J.S.¹¹ Present, D.¹² Sands, B.E.¹³ Colombel, J.F.¹⁴

3
- 33847179443
- A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
- D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
- (2007) Gastroenterology , vol.132 , pp. 763-786
- D'Haens, G.¹ Sandborn, W.J.² Feagan, B.G.³

4
- 32044451548
- Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial
- Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
- (2006) Gastroenterology , vol.130 , pp. 323-333
- Hanauer, S.B.¹ Sandborn, W.J.² Rutgeerts, P.³

5
- 20444479336
- Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study
- DOI 10.1053/j.gastro.2005.03.003, PII S0016508505003847
- Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11. (Pubitemid 40824691)
- (2005) Gastroenterology , vol.128 , Issue.7 , pp. 1805-1811
- Jarnerot, G.¹ Hertervig, E.² Friis-Liby, I.³ Blomquist, L.⁴ Karlen, P.⁵ Granno, C.⁶ Vilien, M.⁷ Strom, M.⁸ Danielsson, A.⁹ Verbaan, H.¹⁰ Hellstrom, P.M.¹¹ Magnuson, A.¹² Curman, B.¹³

6
- 0022622315
- Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease
- Gomes P, du Boulay C, Smith CL, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92-5.
- (1986) Gut , vol.27 , pp. 92-95
- Gomes, P.¹ Du Boulay, C.² Smith, C.L.³

7
- 33750536288
- European Medicines Agency. CHMP/EWP/ 18463/2006. accessed 7 Jan 2011
- European Medicines Agency. Guideline on the Development of New Medicinal Products for the Treatment of Ulcerative Colitis. 2008; CHMP/EWP/ 18463/2006. http://www.tga.gov.au/DOCS/pdf/ euguide/ewp/1846306en.pdf (accessed 7 Jan 2011).
- (2008) Guideline on the Development of New Medicinal Products for the Treatment of Ulcerative Colitis

8
- 75049084134
- Developing the ulcerative colitis endoscopic index of severity(UCEIS): Results of pilot phase
- Travis SPL, Sandborn WJ, Colombel JF, et al. Developing the ulcerative colitis endoscopic index of severity(UCEIS): results of pilot phase. Gut 2008;57SII:A201.
- (2008) Gut , vol.57 SII
- Travis, S.P.L.¹ Sandborn, W.J.² Colombel, J.F.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.